Chronic obstructive pulmonary disease and bone health: A review on possible links and follow up studies

Document Type : Narrative Review

Authors

1 Endocrinologist, Endocrine Research Center,School of Medicine,Mashhad University of Medical Sciences,Mashhad,Iran.

2 Pulmonologist, Lung Diseases Research Center, Mashhad University Medical Science, Mashhad, Iran.

Abstract

Chronic obstructive pulmonary disease (COPD) is a common multisystem disease mostly affecting the respiratory system. Despite the well-known pulmonary manifestations of COPD, the extrapulmonary complications are mainly demonstrated in clinical studies, and the exact mechanisms behind the relationship between COPD and some extrapulmonary manifestations are still unclear. Many case-control studies reported osteoporosis as a common complication of COPD. However, the possible causality between COPD and osteoporosis is not clearly understood, and a lack of follow-up studies on COPD patients is an important issue addressed in the literature. In the present review, we discussed the common molecular pathways in COPD and osteoporosis and summarized the follow-up studies on COPD patients evaluating the possible changes in bone mass density or the development of fractures in COPD patients.

Keywords

References

1.             Soriano JB, Kendrick PJ, Paulson KR, Gupta V, Abrams EM, Adedoyin RA, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Respiratory Medicine. 2020;8(6):585-96.
2.             Alwan A. WHO (2011) Global Status Report on Non-Communicable Diseases 2010. Geneva: World Health Organization.
3.             Inoue D, Watanabe R, Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. International journal of chronic obstructive pulmonary disease. 2016;11:637-48.
4.             MacNee W. Pathology, pathogenesis, and pathophysiology: BMJ. 2006 May 20;332(7551):1202-4.
5.             Miravitlles M, Ribera A. Understanding the Impact of symptoms on the burden of COPD. Respiratory research. 2017;18(1):67.
6.             Viniol C, Vogelmeier CF. Exacerbations of COPD. 2018;27(147):170103.
7.             Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. British Medical Bulletin. 2020;133(1):105-17.
8.             Tian L, Yang R, Wei L, Liu J, Yang Y, Shao F, et al. Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: A cross-sectional study in Gansu province, Northwestern of China. Medicine. 2017;96(43):e8294.
9.             Jastrzebski D, Lutogniewska W, Ochman M, Margas A, Kowalski K, Wyrwol J, et al. Osteoporosis in patients referred for lung transplantation. European journal of medical research. 2010;15 Suppl 2(Suppl 2):68-71.
10.          Gross NJ. Extrapulmonary effects of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine. 2001;7(2):84-92.
11.          Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. The European respiratory journal. 2009;34(1):209-18.
12.          Graat-Verboom L, Smeenk FWJM, van den Borne BEEM, Spruit MA, Jansen FH, van Enschot JWT, et al. Progression of osteoporosis in patients with COPD: A 3-year follow up study. Respiratory Medicine. 2012;106(6):861-70.
13.          Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest. 2008;134(6):1244-9.
14.          Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest. 2011;139(3):648-57.
15.          Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G, Jurriaans E, et al. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2003;14(11):913-7.
16.          Liao KM, Liang FW, Li CY. Risks of all-cause and site-specific fractures among hospitalized patients with COPD. Medicine. 2016;95(40):e5070.
17.          McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 1998;157(3 Pt 1):704-9.
18.          Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E, for the Osteoporotic Fractures in Men Research G. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporosis International. 2010;21(8):1341-9.
19.          Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, Chatzimavridou-Grigoriadou V, Siasos G, Evangelopoulou E, et al. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? Respirology (Carlton, Vic). 2013;18(1):147-53.
20.          Liu SF, Kuo HC, Liu GH, Ho SC, Chang HC, Huang HT, et al. Inhaled corticosteroids can reduce osteoporosis in female patients with COPD. International journal of chronic obstructive pulmonary disease. 2016;11:1607-14.
21.          Kiyokawa H, Muro S, Oguma T, Sato S, Tanabe N, Takahashi T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. Copd. 2012;9(3):235-42.
22.          van Dort MJ, Driessen JHM, Geusens P, Romme E, Smeenk F, Wouters EFM, et al. Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2019;30(8):1561-71.
23.          Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? The Lancet. 2007;370(9589):797-9.
24.          Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-80.
25.          Liang B, Feng Y. The association of low bone mineral density with systemic inflammation in clinically stable COPD. Endocrine. 2012;42(1):190-5.
26.          Teitelbaum SL. Osteoclasts: what do they do and how do they do it? The American journal of pathology. 2007;170(2):427-35.
27.          Lacativa PG, Farias ML. Osteoporosis and inflammation. Arquivos brasileiros de endocrinologia e metabologia. 2010;54(2):123-32.
28.          Chen Y, Bai P, Liu L, Han J, Zeng H, Sun YJIjomm. Increased RANKL expression in peripheral T cells is associated with decreased bone mineral density in patients with COPD. 2016;38(2):585-93.
29.          Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best practice & research Clinical endocrinology & metabolism. 2011;25(4):585-91.
30.          Dimai HP, Domej W, Leb G, Lau K-HW. Bone Loss in Patients with Untreated Chronic Obstructive Pulmonary Disease Is Mediated by an Increase in Bone Resorption Associated with Hypercapnia. 2001;16(11):2132-41.
31.          Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. Journal of applied physiology (Bethesda, Md : 1985). 2013;114(9):1253-62.
32.          De Laet C, Kanis JA, Odén A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2005;16(11):1330-8.
33.          Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. American journal of respiratory and critical care medicine. 2006;173(1):79-83.
34.          Morrison D, Ali N, Routledge P, Capewell SJT. Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease. 1992;47(6):418-20.
35.          Van Staa T, Leufkens H, Cooper CJOi. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. 2002;13(10):777-87.
36.          Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. Declining Bone Mass in Men With Chronic Pulmonary Disease. Chest. 1999;116(6):1616-24.
37.          Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2004;170(7):760-5.
38.          Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. The American journal of medicine. 2003;114(2):142-5.
39.          Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest. 2007;132(5):1599-607.
 
Journal of Cardio-Thoracic Medicine
Volume 8, Issue 4
December 2020
Pages 684-692

Files

Share

How to cite

Statistics